- Home
- ABEO vs NMAI Comparison
ABEO vs NMAI Comparison
Compare ABEO & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | NMAI |
|---|---|---|
| Founded | 1974 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 468.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | NMAI |
|---|---|---|
| Price | $5.05 | $14.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 73.1K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $804.33 | N/A |
| Revenue Next Year | $119.68 | N/A |
| P/E Ratio | ★ N/A | $22.34 |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $11.99 |
| 52 Week High | $7.65 | $15.06 |
Technical Indicators
Market Signals| Indicator | ABEO | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 54.63 |
| Support Level | $4.94 | $13.61 |
| Resistance Level | $5.46 | $15.06 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 11.39 | 86.59 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.